Transforming the treatment of luminal disease.*
To fundamentally transform the treatment of luminal diseases using our patented technology for covering stents with collagen derived from amniotic membrane.
Lumens are tubes and chambers found throughout the body, including airways in the lungs, arteries and veins, and the gastrointestinal and urinary tracts. Luminal diseases are conditions that enlarge, restrict or obstruct those lumens. (The first indication FDA clearance will be sought for is tracheobronchial strictures caused by malignant neoplasms.)
"It is the responsibility of those of us involved in today's biomedical research enterprise to translate the remarkable scientific innovations we are witnessing into health gains for the nation. At no other time has the need for robust, bidirectional information flow between basic and translations scientist been so necessary."
Former Director of the National Institutes of Health
Cofounder, CEO & Chairman
John has 35 years of experience in executive management, sales and marketing, as well as product and business development for medical device and pharmaceutical companies. He has expertise in the interventional and surgical sectors of the pulmonary, gastroenterology, trans-vascular, structural heart, and pharmaceutical markets. Formerly, John served as General Manager for the Global Pharmaceutical Injectable Division of Baxter International, President and General Manager of SuperDimension, Inc. and President and CEO of HeartStent. Prior to those positions, John was Vice President and Business Unit Manager for the Schneider Division of Pfizer and Vice President for Boston Scientific.